ClinicalTrials.gg
CompletedNCT04054921TRANSCENDUpdated Jul 16, 2021

Safety Study for Beta Thalassemia Subjects on PTG-300

A Phase 2 interventional study of PTG-300 in β-thalassemia and Ineffective Erythropoiesis, sponsored by Protagonist Therapeutics, Inc.. Completed at 16 sites in 8 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-07-16.

Sponsored by Protagonist Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2020, 6 years 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2021.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Thalassemia with a site in Thailand — none open to participants now, 3 under way, 2 of them phase 3. Thalassemia · Thailand.

Enrollment
15th of 22
34 · median 99
Started
2019
with 1 other
Phase 2
11 of 24
none open now
Registered
18th of 24
by date
Lead sponsor
2 of 24
Protagonist Therapeutics, Inc.

Among the 24 studies in Thalassemia with a site in Thailand, this one is the 15th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2019, is one of 11 in phase 2, and was the 18th registered.

Thalassemia

250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.

Browse Thalassemia studies →

Open to participants now

None of the 24 studies in Thalassemia with a site in Thailand is open now. The open studies under Thalassemia, anywhere →

Who these studies take

Of the 28 Thalassemia studies recruiting now, 7 (25%) set no upper age limit and 18 (64%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies in Thalassemia with a site in Thailand as a file.
02

Study summary

In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.

Read the detailed description

The PTG-300-03 study will study beta thalassemia patients on PTG-300 for two years. The dose and dose frequency for each subject enrolling in the PTG-300-03 study will be based on the last dose and frequency received by the subject in the previous study PTG-300-02 and the subject's response at that dose. Patients dose will be increased in a manner similar to that used on PTG-300-02 study. The maximum PTG-300 dose allowed is 80 mg/week.

03

Conditions studied

  • β-thalassemia
  • Ineffective Erythropoiesis

Browse trials for

Keywords

  • Chronic anemia
  • β-thalassemia
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • NTD and TD β-thalassemia subjects who completed Week 12 and Week 16 respectively in Study PTG-300-02.

Exclusion criteria

Exclusion Criteria:

  • Subjects who discontinued prematurely from study 300-02 (before Week 12 in NTD and Week 16 in TD).
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Interventions

    PTG-300

    Drug: PTG-300

Interventions

  • PTG-300 is a hepcidin Mimetic

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with side effects and severity of side effects will be tabulated

    the long-term safety and tolerability of PTG-300 in Beta Thalassemia.

    Time frame: Over two year Period after receiving PTG-300

07

Study locations

16 sites
  • UCSF Benioff Children's Hospital
    Oakland, California 94609, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02215, United States
  • Laiko General Hospital of Athens
    Athens, 11526, Greece
  • Athens General Hospital 'G Gennimatas'
    Athens, 11527, Greece
  • University General Hospital of Patras
    Patras, 26500, Greece
  • Chronic Care Center
    Hazmiyeh, Lebanon
  • Hospital Ampang
    Ampang, 68000, Malaysia
  • Hospital Umum Sarawak
    Kuching, 93586, Malaysia
  • Siriraj Hospital Mahidol University
    Bangkok, 10700, Thailand
  • Khon Kaen University
    Khon Kaen, 40002, Thailand
  • Chulalongkorn University
    Pathum Wan, 10330, Thailand
  • Naresuan University
    Phitsanulok, 65000, Thailand
  • University Hospital Farhat Hached
    Sousse, 4000, Tunisia
  • Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi
    Istanbul, 34093, Turkey
  • Ege Universitesi Tip Fakultesi
    Izmir, 35100, Turkey
  • Barts Health NHS Trust
    London, E1 1BB, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Jul 2020, 14 months.

Of 25 phase 2 interventional studies under Thalassemia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 67. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2019
First posted
Aug 13, 2019
StartActual
May 10, 2019
Primary completionActual
Jul 31, 2020
CompletionActual
Jul 31, 2020
Results delay requested
Jul 9, 2021
Last update
Jul 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04054921
Lead sponsor
Protagonist Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 13, 2019
Start date
May 10, 2019
Primary completion
Jul 31, 2020
Completion
Jul 31, 2020
Last update
Jul 16, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rusfertide

Start the discussion